Lopez-Martinez D, et al. (2019) Phosphorylation of FANCD2 Inhibits the FANCD2/FANCI Complex and Suppresses the Fanconi Anemia Pathway in the Absence of DNA Damage. Cell Rep 27, 2990-3005.e5 31167143

This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.

Information from this record has been curated, but not yet edited in PhosphoSitePlus® and may be incomplete.

Click on the protein name to open the protein page, and on the RSD number to open the site page.

Download

S882-p - FANCD2 (human) ▲

Modsite: DGSkTSSsDtLsEEk SwissProt Entrez-Gene Orthologous residues FANCD2 (human): S882‑p, FANCD2 iso1 (human): S882‑p, FANCD2 iso3 (human): S882‑p, FANCD2 (mouse): S880‑p, FANCD2 (rat): T882‑p, FANCD2 (chicken): A880‑p Characterization Methods used to characterize site in vivo:  immunoprecipitation, mass spectrometry, mutation of modification site Disease tissue studied:  cervical cancer, cervical adenocarcinoma Relevant cell lines - cell types - tissues:  HeLa (cervical), HeLa S3 (cervical) Cellular systems studied:  cell lines Species studied:  human Upstream Regulation Potential in vivo enzymes for site:  Type Enzyme Evidence Notes KINASE CK2A1 (human) pharmacological inhibitor of upstream enzyme Comments:  882-898 cluster Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes silmitasertib decrease Downstream Regulation Effect of modification (function):  activity, inhibited, intracellular localization, molecular association, regulation, ubiquitination Effect of modification (process):  cell cycle regulation, DNA repair, inhibited, signaling pathway regulation Modification regulates interactions with:  Interacting molecule Interacting domains Effect Consequences (function) Consequences (process) Detection assays Disrupts Comments:  882-898 cluster; inhibits Fanconi anemia pathway leading to inhibition of DNA repair

T884-p - FANCD2 (human) ▲

Modsite: SkTSSsDtLsEEkNs SwissProt Entrez-Gene Orthologous residues FANCD2 (human): T884‑p, FANCD2 iso1 (human): T884‑p, FANCD2 iso3 (human): T884‑p, FANCD2 (mouse): T882‑p, FANCD2 (rat): T884‑p, FANCD2 (chicken): R882‑p Characterization Methods used to characterize site in vivo:  immunoprecipitation, mass spectrometry, mutation of modification site Disease tissue studied:  cervical cancer, cervical adenocarcinoma Relevant cell lines - cell types - tissues:  HeLa (cervical), HeLa S3 (cervical) Cellular systems studied:  cell lines Species studied:  human Upstream Regulation Potential in vivo enzymes for site:  Type Enzyme Evidence Notes KINASE CK2A1 (human) pharmacological inhibitor of upstream enzyme Comments:  882-898 cluster Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes silmitasertib decrease Downstream Regulation Effect of modification (function):  activity, inhibited, intracellular localization, molecular association, regulation, ubiquitination Effect of modification (process):  cell cycle regulation, DNA repair, inhibited, signaling pathway regulation Modification regulates interactions with:  Interacting molecule Interacting domains Effect Consequences (function) Consequences (process) Detection assays Disrupts Comments:  882-898 cluster; inhibits Fanconi anemia pathway leading to inhibition of DNA repair

S886-p - FANCD2 (human) ▲

Modsite: TSSsDtLsEEkNsEC SwissProt Entrez-Gene Orthologous residues FANCD2 (human): S886‑p, FANCD2 iso1 (human): S886‑p, FANCD2 iso3 (human): S886‑p, FANCD2 (mouse): L884‑p, FANCD2 (rat): L886‑p, FANCD2 (chicken): Q884‑p Characterization Methods used to characterize site in vivo:  immunoprecipitation, mass spectrometry, mutation of modification site Disease tissue studied:  cervical cancer, cervical adenocarcinoma Relevant cell lines - cell types - tissues:  HeLa (cervical), HeLa S3 (cervical) Cellular systems studied:  cell lines Species studied:  human Enzymes shown to modify site in vitro:  Type Enzyme KINASE CK2A1 (human) Upstream Regulation Potential in vivo enzymes for site:  Type Enzyme Evidence Notes KINASE CK2A1 (human) pharmacological inhibitor of upstream enzyme Comments:  882-898 cluster Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes silmitasertib decrease Downstream Regulation Effect of modification (function):  activity, inhibited, intracellular localization, molecular association, regulation, ubiquitination Effect of modification (process):  cell cycle regulation, DNA repair, inhibited, signaling pathway regulation Modification regulates interactions with:  Interacting molecule Interacting domains Effect Consequences (function) Consequences (process) Detection assays Disrupts Comments:  882-898 cluster; inhibits Fanconi anemia pathway leading to inhibition of DNA repair

S891-p - FANCD2 (human) ▲

Modsite: tLsEEkNsECDPtPs SwissProt Entrez-Gene Orthologous residues FANCD2 (human): S891‑p, FANCD2 iso1 (human): S891‑p, FANCD2 iso3 (human): S891‑p, FANCD2 (mouse): S889‑p, FANCD2 (rat): S891‑p, FANCD2 (chicken): S889‑p Characterization Methods used to characterize site in vivo:  immunoprecipitation, mass spectrometry, mutation of modification site Disease tissue studied:  cervical cancer, cervical adenocarcinoma Relevant cell lines - cell types - tissues:  HeLa (cervical), HeLa S3 (cervical) Cellular systems studied:  cell lines Species studied:  human Upstream Regulation Potential in vivo enzymes for site:  Type Enzyme Evidence Notes KINASE CK2A1 (human) pharmacological inhibitor of upstream enzyme Comments:  882-898 cluster Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes silmitasertib decrease Downstream Regulation Effect of modification (function):  activity, inhibited, intracellular localization, molecular association, regulation, ubiquitination Effect of modification (process):  cell cycle regulation, DNA repair, inhibited, signaling pathway regulation Modification regulates interactions with:  Interacting molecule Interacting domains Effect Consequences (function) Consequences (process) Detection assays Disrupts Comments:  882-898 cluster; inhibits Fanconi anemia pathway leading to inhibition of DNA repair

T896-p - FANCD2 (human) ▲

Modsite: kNsECDPtPsHRGQL SwissProt Entrez-Gene Orthologous residues FANCD2 (human): T896‑p, FANCD2 iso1 (human): T896‑p, FANCD2 iso3 (human): T896‑p, FANCD2 (mouse): A894‑p, FANCD2 (rat): A896‑p, FANCD2 (chicken): P894‑p Characterization Methods used to characterize site in vivo:  immunoprecipitation, mass spectrometry, mutation of modification site Disease tissue studied:  cervical cancer, cervical adenocarcinoma Relevant cell lines - cell types - tissues:  HeLa (cervical), HeLa S3 (cervical) Cellular systems studied:  cell lines Species studied:  human Enzymes shown to modify site in vitro:  Type Enzyme KINASE CK2A1 (human) Upstream Regulation Potential in vivo enzymes for site:  Type Enzyme Evidence Notes KINASE CK2A1 (human) pharmacological inhibitor of upstream enzyme Comments:  882-898 cluster Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes silmitasertib decrease Downstream Regulation Effect of modification (function):  activity, inhibited, intracellular localization, molecular association, regulation, ubiquitination Effect of modification (process):  cell cycle regulation, DNA repair, inhibited, signaling pathway regulation Modification regulates interactions with:  Interacting molecule Interacting domains Effect Consequences (function) Consequences (process) Detection assays Disrupts Comments:  882-898 cluster; inhibits Fanconi anemia pathway leading to inhibition of DNA repair

S898-p - FANCD2 (human) ▲

Modsite: sECDPtPsHRGQLNk SwissProt Entrez-Gene Orthologous residues FANCD2 (human): S898‑p, FANCD2 iso1 (human): S898‑p, FANCD2 iso3 (human): S898‑p, FANCD2 (mouse): S896‑p, FANCD2 (rat): S898‑p, FANCD2 (chicken): T896‑p Characterization Methods used to characterize site in vivo:  immunoprecipitation, mass spectrometry, mutation of modification site Disease tissue studied:  cervical cancer, cervical adenocarcinoma Relevant cell lines - cell types - tissues:  HeLa (cervical), HeLa S3 (cervical) Cellular systems studied:  cell lines Species studied:  human Upstream Regulation Potential in vivo enzymes for site:  Type Enzyme Evidence Notes KINASE CK2A1 (human) pharmacological inhibitor of upstream enzyme Comments:  882-898 cluster Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes silmitasertib decrease Downstream Regulation Effect of modification (function):  activity, inhibited, intracellular localization, molecular association, regulation, ubiquitination Effect of modification (process):  cell cycle regulation, DNA repair, inhibited, signaling pathway regulation Modification regulates interactions with:  Interacting molecule Interacting domains Effect Consequences (function) Consequences (process) Detection assays Disrupts Comments:  882-898 cluster; inhibits Fanconi anemia pathway leading to inhibition of DNA repair

S1257-p - FANCD2 (human) ▲

Modsite: EPGtAADsQQIHEEK SwissProt Entrez-Gene Orthologous residues FANCD2 (human): S1257‑p, FANCD2 iso1 (human): S1257‑p, FANCD2 iso3 (human): ‑, FANCD2 (mouse): S1255‑p, FANCD2 (rat): S1257‑p, FANCD2 (chicken): S1257‑p Characterization Methods used to characterize site in vivo:  mass spectrometry Relevant cell lines - cell types - tissues:  HeLa (cervical) Cellular systems studied:  cell lines Species studied:  human

S1401-p - FANCD2 (human) ▲

Modsite: LQGEEIKsQNsQEst SwissProt Entrez-Gene Orthologous residues FANCD2 (human): S1401‑p, FANCD2 iso1 (human): S1401‑p, FANCD2 iso3 (human): ‑, FANCD2 (mouse): S1399‑p, FANCD2 (rat): S1401‑p, FANCD2 (chicken): S1401‑p Characterization Methods used to characterize site in vivo:  mass spectrometry Relevant cell lines - cell types - tissues:  HeLa (cervical) Cellular systems studied:  cell lines Species studied:  human

S1404-p - FANCD2 (human) ▲

Modsite: EEIKsQNsQEstADE SwissProt Entrez-Gene Orthologous residues FANCD2 (human): S1404‑p, FANCD2 iso1 (human): S1404‑p, FANCD2 iso3 (human): ‑, FANCD2 (mouse): S1404‑p, FANCD2 (rat): S1406‑p, FANCD2 (chicken): A1406‑p Characterization Methods used to characterize site in vivo:  mass spectrometry Relevant cell lines - cell types - tissues:  HeLa (cervical) Cellular systems studied:  cell lines Species studied:  human

S1407-p - FANCD2 (human) ▲

Modsite: KsQNsQEstADEsED SwissProt Entrez-Gene Orthologous residues FANCD2 (human): S1407‑p, FANCD2 iso1 (human): S1407‑p, FANCD2 iso3 (human): ‑, FANCD2 (mouse): S1407‑p, FANCD2 (rat): N1409‑p, FANCD2 (chicken): ‑ Characterization Methods used to characterize site in vivo:  mass spectrometry Relevant cell lines - cell types - tissues:  HeLa (cervical) Cellular systems studied:  cell lines Species studied:  human